Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Critical Care Medicine|December 31, 2008
The clinical effectiveness of central venous catheters treated with anti-infective agents in preventing catheter-related bloodstream infections: a systematic reviewJuliet C Hockenhull, Kerry M Dwan, Godfrey W Smith, et al.
Pharmacoeconomics|April 24, 2015
Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group PerspectiveNigel Fleeman, Adrian Bagust, Sophie Beale, et al.
Pharmacoeconomics - Open|September 21, 2023
Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15Marty Chaplin, Rebecca Bresnahan, Nigel Fleeman, et al.
Pharmacoeconomics|March 31, 2018
Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology AppraisalAngela Stainthorpe, Janette Greenhalgh, Adrian Bagust, et al.
Pharmacoeconomics|November 28, 2017
Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology AppraisalNigel Fleeman, Ahmed Abdulla, Adrian Bagust, et al.
Pharmacoeconomics|April 12, 2013
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisalJanette Greenhalgh, Adrian Bagust, Angela Boland, et al.
Pharmacoeconomics - Open|April 16, 2020
Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology AppraisalRachel Houten, Janette Greenhalgh, James Mahon, et al.
Pharmacoeconomics|October 18, 2018
Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology AppraisalTosin Lambe, Rui Duarte, James Mahon, et al.
Health Technology Assessment (Winchester, England)|April 22, 2015
Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysisJanette Greenhalgh, Adrian Bagust, Angela Boland, et al.
Personalized Medicine|May 20, 2018
Are health technology assessments of pharmacogenetic tests feasible? A case study of CYP2D6 testing in the treatment of breast cancer with tamoxifenNigel Fleeman, Katherine Payne, William G Newman, et al.
Pageof 6